Reviva Pharmaceuticals Holdings Inc. (RVPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Reviva Pharmaceuticals Holdings Inc. (RVPH) has a cash flow conversion efficiency ratio of -2.844x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.59 Trillion) by net assets ($8.65 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Reviva Pharmaceuticals Holdings Inc. to measure how much of total assets are equity-financed.
Reviva Pharmaceuticals Holdings Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Reviva Pharmaceuticals Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Reviva Pharmaceuticals Holdings Inc. to evaluate the quality of earnings relative to operating cash generation.
Reviva Pharmaceuticals Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Reviva Pharmaceuticals Holdings Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clearmind Medicine Inc. Common Shares
NASDAQ:CMND
|
-0.253x |
|
Boqii Holding Limited
NYSE:BQ
|
0.002x |
|
Vsolar Group Bhd
KLSE:0066
|
-0.083x |
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
-0.167x |
|
Superior Resources Ltd
AU:SPQ
|
-0.025x |
|
Pembangunan Graha Lestari Tbk
JK:PGLI
|
0.016x |
|
Intan Baruprana Finance Tbk
JK:IBFN
|
-0.021x |
|
Global Interactive Technologies, Inc
NASDAQ:GITS
|
-0.032x |
Annual Cash Flow Conversion Efficiency for Reviva Pharmaceuticals Holdings Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Reviva Pharmaceuticals Holdings Inc. from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Reviva Pharmaceuticals Holdings Inc. stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.65 Trillion | $-24.59 Trillion | -2.844x | +93.11% |
| 2024-12-31 | $812.57K | $-33.54 Million | -41.281x | -733.47% |
| 2023-12-31 | $5.72 Million | $-28.32 Million | -4.953x | -119.28% |
| 2022-12-31 | $8.39 Million | $-18.96 Million | -2.259x | -507.36% |
| 2021-12-31 | $28.69 Million | $-10.67 Million | -0.372x | +50.01% |
| 2020-12-31 | $5.47 Million | $-4.07 Million | -0.744x | -2419.97% |
| 2019-12-31 | $-6.81 Million | $-218.44K | 0.032x | +277.08% |
| 2018-12-31 | $59.16 Million | $-1.07 Million | -0.018x | -- |
About Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, s… Read more